keyword
MENU ▼
Read by QxMD icon Read
search

Ceftolozane

keyword
https://www.readbyqxmd.com/read/28386491/multidrug-resistant-pseudomonas-mycotic-pseudoaneurysm-following-cardiac-transplant-bridged-by-ventricular-assistant-device
#1
C Aye, M Williams, R Horvath
Mycotic pseudoaneurysm of aorta following cardiac surgery is rare but is highly fatal if it is unrecognized and untreated. Here, we report a case of a 45-year-old male patient who presented with rapidly progressive multiple pseudoaneurysms of the ascending aorta infected with multidrug resistant (MDR) Pseudomonas aeruginosa at 5 weeks after cardiac transplantation, on a background of prior bridging therapy with left ventricular assistant device (LVAD). The patient was successfully treated with the newer cephalosporin, Ceftolozane/Tazobactam, in combination with surgery...
2017: Case Reports in Infectious Diseases
https://www.readbyqxmd.com/read/28369471/activity-of-cefiderocol-s-649266-against-carbapenem-resistant-gram-negative-bacteria-collected-from-inpatients-in-greek-hospitals
#2
Matthew E Falagas, Tilemachos Skalidis, Konstantinos Z Vardakas, Nicholas J Legakis
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases. Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline...
March 22, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28363945/successful-treatment-of-multidrug-resistant-pseudomonas-aeruginosa-pubic-symphysis-osteomyelitis-with-ceftolozane-tazobactam
#3
Kari E Kurtzhalts, Kari A Mergenhagen, Akshay Manohar, Charles S Berenson
New antibiotic options are needed for the treatment of multidrug-resistant (MDR) Pseudomonas infections. We present a case of a man aged 64 years with a bladder fistula due to radiation, ultimately causing osteomyelitis of the pubic symphysis. Repeated antibiotic courses, without correcting the fistula, resulted in infection with MDR Pseudomonas aeruginosa. He was successfully treated for his osteomyelitis through cystectomy, aggressive debridement and a prolonged course of antimicrobials directed at the MDR Pseudomonas isolate...
March 31, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28362938/the-use-of-noncarbapenem-%C3%AE-lactams-for-the-treatment-of-extended-spectrum-%C3%AE-lactamase-infections
#4
Pranita D Tamma, Jesus Rodriguez-Bano
The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae...
April 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28361526/ceftolozane-tazobactam-for-the-treatment-of-ventilator-associated-infections-by-colistin-resistant-pseudomonas-aeruginosa
#5
F Álvarez Lerma, R Muñoz Bermudez, S Grau, M P Gracia Arnillas, L Sorli, L Recasens, M Mico García
The use of colistin for the treatment of multiresistant bacteria has led to the emergence of colistin-resistant strains of Gram-negative bacilli. Treatment of infections caused by these pan-drug-resistant bacteria is difficult owing to the paucity of effective antibiotics. We report two cases of ventilator-associated respiratory infection caused by pan-drug-resistant, colistin-resistant Pseudomonas aeruginosa that were successfully treated with ceftolozane-tazobactam.
March 29, 2017: Revista Española de Quimioterapia: Publicación Oficial de la Sociedad Española de Quimioterapia
https://www.readbyqxmd.com/read/28351154/use-of-continuous-infusion-ceftolozane-tazobactam-in-a-multidrug-resistant-pseudomonas-aeruginosa-urinary-tract-infection-in-the-outpatient-setting
#6
Bruce M Jones, Bradley Smith, Christopher M Bland
No abstract text is available yet for this article.
March 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28329350/multicenter-evaluation-of-ceftolozane-tazobactam-for-serious-infections-caused-by-carbapenem-resistant-pseudomonas-aeruginosa
#7
Jose M Munita, Samuel L Aitken, William R Miller, Federico Perez, Rossana Rosa, Luis A Shimose, Paola N Lichtenberger, Lilian M Abbo, Rupali Jain, Masayuki Nigo, Audrey Wanger, Rafael Araos, Truc T Tran, Javier Adachi, Robert Rakita, Samuel Shelburne, Robert A Bonomo, Cesar A Arias
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
March 14, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28314920/-new-antibiotics-standstill-or-progress
#8
J Rademacher, T Welte
The development of resistance to antibiotics has been ignored for a long time. But nowadays, increasing resistance is an important topic. For a decade no new antibiotics had been developed and it is not possible to quickly close this gap of new resistance and no new drugs. This work presents six new antibiotics (ceftaroline, ceftobiprole, solithromycin, tedizolid, ceftolozane/tazobactam, ceftazidime/avibactam). In part, only expert opinions are given due to lack of study results.The two 5th generation cephalosporins ceftaroline and ceftobiprole have beside their equivalent efficacy to ceftriaxone (ceftaroline) and cefipim (ceftobiprole) high activity against MRSA...
March 17, 2017: Medizinische Klinik, Intensivmedizin und Notfallmedizin
https://www.readbyqxmd.com/read/28237981/ex-vivo-ceftolozane-tazobactam-clearance-during-continuous-renal-replacement-therapy
#9
Weerachai Chaijamorn, Alexander R Shaw, Susan J Lewis, Bruce A Mueller
BACKGROUND/AIMS: To determine ceftolozane/tazobactam transmembrane clearances (CLTM) in continuous hemofiltration (CHF) and continuous hemodialysis (CHD) and to determine optimal ceftolozane/tazobactam dosing regimens for patients receiving continuous renal replacement therapy (CRRT). METHOD: Validated, ex vivo CHF and CHD bovine blood models using polysulfone (HF1400) and AN69 (Multiflow 150-M) hemofilters were used to evaluate adsorption and CLTM at different effluent flow rates...
2017: Blood Purification
https://www.readbyqxmd.com/read/28203427/potency-of-parenteral-antimicrobials-including-ceftolozane-tazobactam-against-nosocomial-respiratory-tract-pathogens-considerations-for-empiric-and-directed-therapy
#10
Christina A Sutherland, David P Nicolau
BACKGROUND: Empiric therapy decisions are predicated on knowledge of both the epidemiology and antimicrobial susceptibility of the probable infecting pathogen(s). The objective of this study was to evaluate the microbial distribution and phenotypic profiles of nosocomial respiratory isolates collected from multiple US hospitals and assess the clinical utility of various monotherapy and combination regimens. METHODS: Hospitals provided consecutive non-duplicate adult inpatients Gram-negative nosocomial respiratory isolates from cultures received ≥48 h after hospital admission...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28165526/ceftolozane-tazobactam-activity-against-drug-resistant-enterobacteriaceae-and-pseudomonas-aeruginosa-causing-urinary-tract-and-intraabdominal-infections-in-europe-report-from-an-antimicrobial-surveillance-programme-2012-15
#11
Michael A Pfaller, Matteo Bassetti, Leonard R Duncan, Mariana Castanheira
No abstract text is available yet for this article.
February 6, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28134677/are-there-any-reasons-to-change-our-behavior-in-necrotizing-fasciitis-with-the-advent-of-new-antibiotics
#12
Francesco Menichetti, Simone Giuliano, Simona Fortunato
PURPOSE OF REVIEW: The treatment of necrotizing fasciitis requires a multifaceted approach, consisting of surgical source control with immediate surgical debridement along with life support, clinical monitoring, and antimicrobial therapy. Many drugs are now available for the treatment of this life-threatening infectious disease, and the purpose of this review is to provide the reader with an updated overview of the newest therapeutic options. RECENT FINDINGS: Because most necrotizing soft tissue infections are polymicrobial, broad-spectrum coverage is advisable...
April 2017: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/28096165/in-vitro-activity-of-ceftolozane-tazobactam-against-multidrug-resistant-nonfermenting-gram-negative-bacilli-isolated-from-patients-with-cystic-fibrosis
#13
Patrick Grohs, Gary Taieb, Philippe Morand, Iheb Kaibi, Isabelle Podglajen, Marie Lavollay, Jean-Luc Mainardi, Fabrice Compain
Ceftolozane-tazobactam was tested against 58 multidrug-resistant nonfermenting Gram-negative bacilli (35 Pseudomonas aeruginosa, 11 Achromobacter xylosoxydans, and 12 Stenotrophomonas maltophilia isolates) isolated from cystic fibrosis patients and was compared to ceftolozane alone, ceftazidime, meropenem, and piperacillin-tazobactam. Ceftolozane-tazobactam was the most active agent against P. aeruginosa but was inactive against A. xylosoxydans and S. maltophilia In time-kill experiments, ceftolozane-tazobactam had complete bactericidal activity against 2/6 clinical isolates (33%)...
April 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28013453/pk-pd-target-attainment-with-ceftolozane-tazobactam-using-monte-carlo-simulation-in-patients-with-various-degrees-of-renal-function-including-augmented-renal-clearance-and-end-stage-renal-disease
#14
Alan J Xiao, Luzelena Caro, Myra W Popejoy, Jennifer A Huntington, Ravina Kullar
INTRODUCTION: Ceftolozane/tazobactam is an antibacterial agent with potent in vitro activity against Gram-negative pathogens, including many extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa. Because ceftolozane/tazobactam is primarily excreted renally, appropriate dose adjustments are needed for patients with renal impairment. Monte Carlo simulations were used to determine the probability of pharmacokinetic/pharmacodynamic target attainment for patients with varying degrees of renal function, including augmented renal clearance (ARC) and end-stage renal disease (ESRD) with hemodialysis...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28007721/physical-compatibility-of-ceftolozane-tazobactam-with-selected-i-v-drugs-during-simulated-y-site-administration
#15
Abrar K Thabit, Yukihiro Hamada, David P Nicolau
PURPOSE: Results of a study to examine the physical compatibility of ceftolozane-tazobactam with common i.v. medications during simulated Y-site administration are presented. METHODS: Ceftolozane-tazobactam was reconstituted according to manufacturer recommendations and diluted with 0.9% sodium chloride or 5% dextrose to solutions containing 15 mg (10 mg of ceftolozane and 5 mg of tazobactam)/mL. All other i.v. drugs were prepared according to manufacturer recommendations and diluted with 0...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27999024/does-moderate-renal-impairment-affect-clinical-outcomes-in-complicated-intra-abdominal-and-complicated-urinary-tract-infections-analysis-of-two-randomized-controlled-trials-with-ceftolozane-tazobactam
#16
Ravina Kullar, Florian M Wagenlehner, Myra W Popejoy, Jianmin Long, Brian Yu, Ellie J C Goldstein
Objectives: For reasons not well understood, antibacterials can yield lower cure rates in renally impaired patients. We explored this subject for the novel antibacterial ceftolozane/tazobactam. Methods: ASPECT-complicated intra-abdominal infections (cIAIs) and ASPECT-complicated urinary tract infections (cUTIs) were randomized, double-blinded clinical trials. Analyses in moderate [creatinine clearance (CL CR ) 30-50 mL/min] and mild/no (CL CR  > 50 mL/min) renal impairment (RI) patients were pre-specified as exploratory endpoints in the statistical analysis plans...
March 1, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27988068/in-vivo-pharmacodynamics-of-piperacillin-tazobactam-implications-for-antimicrobial-efficacy-and-resistance-suppression-with-innovator-and-generic-products
#17
COMPARATIVE STUDY
Carlos A Rodriguez, Maria Agudelo, Andres F Zuluaga, Omar Vesga
Recent studies have shown that the pharmacodynamic (PD) index driving the efficacy of β-lactam/β-lactamase inhibitor combinations such as ceftazidime/avibactam and ceftolozane/tazobactam is the percentage of time the free inhibitor concentration is above a threshold (fT>threshold). However, data with piperacillin/tazobactam (TZP) are scarce. Here we aimed to assess the relationship between fT>threshold and TZP antibacterial efficacy by a population pharmacokinetic study in mice and dose-effect experiments in a neutropenic murine thigh infection model with two isogenic strains of Escherichia coli differentially expressing TEM-1 β-lactamase...
February 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27970761/budget-impact-analysis-of-ceftolozane-tazobactam-zerbaxa-for-the-treatment-of-complicated-intra-abdominal-infections-and-complicated-urinary-tract-infections-in-the-italian-setting
#18
M Barbieri, D Crocchiolo, M A Veneziano
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27959289/newer-intravenous-antibiotics-in-the-intensive-care-unit-ceftaroline-ceftolozane-tazobactam-and-ceftazidime-avibactam
#19
Kathryn A Connor
No abstract text is available yet for this article.
October 2016: AACN Advanced Critical Care
https://www.readbyqxmd.com/read/27956431/salvage-therapy-with-ceftolozane-tazobactam-for-multidrug-resistant-pseudomonas-aeruginosa-infections
#20
Juan José Castón, Álvaro De la Torre, Isabel Ruiz-Camps, María Luisa Sorlí, Vicente Torres, Julián Torre-Cisneros
Infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRPA) present a major problem for therapeutic management. We report here our experience with 12 patients with a severe MDRPA infection (6 of which were pneumonia) who received salvage therapy with ceftolozane-tazobactam after inappropriate empirical treatment and/or suboptimal targeted treatment. Although 10 of the 12 patients (83.3%) experienced septic shock, only 3 patients (25%) died during the follow-up period. Microbiological cure in 7 patients (58...
March 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
23428
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"